Loading…
← CockpitCompetitor Analysis › JBIO Jade Biosciences, Inc.Open in the cockpit ↗

Jade Biosciences, Inc.JBIOCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum weak 25
Mkt cap
$1.07B
US dollars, full cap
Free float
86%
of shares outstanding
$/day
$13.2M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 14.1%
Hurdle
n/a
no reverse DCF
Next earnings
133 days
31 Mar 2027
Close · USD$15.49
1D+0.6%
1W-6.3%
1M+4.2%
3M-27.0%
6M-33.6%
YTD+0.4%
1Y+23.0%
ATR %6.6%
Beta1.33
52w lowhigh44.7% off high

What Jade Biosciences does

Employees: 55

Jade Biosciences at a glance

Size Jade Biosciences (JBIO) is a United States Health Care company (Biotechnology) with a market value of $1.07B, the 2188th largest of 3,085 United States companies the cockpit tracks. Shares closed at $15.49 on 18 Nov 2026.

Performance Over six months the shares fell 33.6%, against -16.6% for the median peer and -2.2% for the United States market (cap-weighted) — 4th lowest of 20 in its peer set.

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 83JBIO 66
Six months, rebased to 100: Jade Biosciences against the median of its 20 peers (local-currency closes).

Jade Biosciences financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$43,000-$26,000-$282,000-$96,000-$68,000
EBITDA-$177M-$114M-$74.3M-$81.3M-$53.2M
Net income-$163M-$127M-$69.6M-$75.5M-$51.5M
Free cash flow-$130M-$94.9M-$71.2M-$56.9M-$39.3M
Capital expenditure$3,000$196,000$0$142,000$195,000
Total debt$594,000$724,000$417,000$675,000$1.09M

Quarterly statements and history in the cockpit →

Jade Biosciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%-40%-20%0%9606002030300482VORANROINBXCMPSSGP688276AKUMSMLYS688739000403301207688253ODTX2160JBIO6-month return →1-month return →
Up and to the right = strong over both horizons. Jade Biosciences is the large dot.

Jade Biosciences competitors and peer comparison

How Jade Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jade Biosciences against its 20 peers (data as of 18 Nov 2026)
MeasureJBIOPeer medianRank in peer set
1-month return+4.2%-8.8%3rd highest of 21
6-month return-33.6%-16.6%4th lowest of 20
Distance from 52-week high-44.7%-40.8%9th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Jade Biosciences JBIOUnited States$1.07B-34%n/an/an/an/an/a
Duality Biotherapeutics 9606.HKHong Kong$1.06B-58%-5%-181%5.6×n/an/a
Daan Gene 002030.SZChina$1.05B-17%+1%-81%8.0×4.8%-32.3%
Guangzhou Wondfo Biotech 300482.SZChina$1.05B-18%-24%-2%2.9×14.3%-5.8%
Vor Biopharma VORUnited States$1.10B+15%n/an/an/an/an/a
Alto Neuroscience ANROUnited States$1.04B+25%n/an/an/an/an/a
Inhibrx Biosciences INBXUnited States$1.02B-37%+43%-6,287%551.0×n/an/a
COMPASS Pathways Plc Sponsored ADR CMPSUnited States$1.15B-25%n/an/an/an/an/a
Kardigan KARDUnited States$1.15Bn/an/an/an/an/an/a
SpyGlass Pharma SGPUnited States$993M+36%n/an/an/an/an/a
Changchun BCHT Biotechnology 688276.SSChina$992M-2%+2%-29%9.9×n/an/a
Akums Drugs and Pharmaceuticals AKUMS.NSIndia$1.21B+38%+18%10%2.0×15.3%+9.9%
Mineralys Therapeutics MLYSUnited States$1.22B-52%n/an/an/an/an/a
Liaoning Chengda Biotechnology 688739.SSChina$1.22B-14%-9%0%2.2×6.6%-7.0%
Pacific Shuanglin Bio-pharmacy 000403.SZChina$1.24B-21%+1%10%3.5×n/an/a
China Animal Husbandry Industry 600195.SSChina$921M-16%+1%2%1.3×6.1%+4.4%
Hualan Biological Vaccine 301207.SZChina$1.25B-29%-28%-7%9.0×33.2%-13.1%
Innovita Biological Technology 688253.SSChina$915M-28%-28%11%14.0×39.6%-16.6%
Odyssey Therapeutics ODTXUnited States$912M+12%-33%-5,415%204.9×n/an/a
Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZChina$909M-15%0%22%4.2×9.2%+2.3%
GNI 2160.TJapan$903M-25%+44%-21%6.2×n/an/a

Questions

Which companies are Jade Biosciences's closest peers?
The cockpit's peer set: Duality Biotherapeutics (9606.HK), Daan Gene (002030.SZ), Guangzhou Wondfo Biotech (300482.SZ), Vor Biopharma (VOR), Alto Neuroscience (ANRO), Inhibrx Biosciences (INBX), COMPASS Pathways Plc Sponsored ADR (CMPS), Kardigan (KARD).
How has Jade Biosciences stock performed?
Over six months to 18 Nov 2026 the shares returned -33.6% against -16.6% for the median peer; over one year +23.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.